

# MONTHLY MEDICATION SAFETY UPDATE

## Information for health professionals in NSW public health organisations

This is a summary of medication safety and supply related issues affecting NSW public health facilities in **July 2026**. Updates regarding current medication-specific safety and supply related issues are available on the [CEC website](#).

### Medication Safety and Supply Summary

|     |                                                                         |
|-----|-------------------------------------------------------------------------|
| 106 | Safety/supply issues requiring investigation by the CEC                 |
| 24  | Reported to the frontline due to safety risk requiring local mitigation |
| 1   | Formal safety communication developed                                   |
| 14  | Previous issues resolved on CEC Medication Safety Updates table         |

### CEC updates:

- The Australian Commission on Safety and Quality in Health Care has published new national guidance for the safe, appropriate and sustainable use of intravenous (IV) fluids: Guidance – [Intravenous fluid therapy: Principles for safe, appropriate and sustainable use](#), Guidance – [Safe administration of intravenous fluids: Avoiding venous air embolism](#), [Fact sheet for prescribers of IV fluid therapy](#) and [Poster for clinicians](#).
- On **5 November 2026** the new *Medicines, Poisons and Therapeutic Goods Act 2022* and its supporting Regulation will commence, replacing the *Poisons and Therapeutic Goods Act 1966* and its Regulation.

### Therapeutic Goods Administration (TGA) updates:

- Product Information safety updates: July 2026*
- Safety alerts and updates:*
  - [ITCHA SSS capsules](#), marketed for weight management, have been found to contain oxedrine, an undisclosed prescription-only (Schedule 4) medicine.
  - [Unapproved SARMS found to be significantly underdosed](#)
  - Cases of liver injury associated with [herbal preparations containing \*Withania somnifera\* \(\*W. somnifera\*\)](#), commonly known as Ashwagandha, continue to be reported both in Australia and internationally.
  - [Counterfeit 'honey' sachets for sexual enhancement](#)
  - [TGA review of the benefits and risks of TAVNEOS \(avacopan\)](#)

### Safety Broadcasts released

SN:013/26 – [Planned changes to enoxaparin \(Clexane®\) injection safety lock system](#)  
– 9 July 2026 (intranet only)

### Medications reported on CEC Medication Safety Updates table this month:

- Acarbose tablets
- Argipressin 20 units/mL injection
- Benzathine benzylpenicillin injections
- Betaxolol 0.5% eye drops
- Buprenorphine (Sublocade) modified release injections
- Cyclophosphamide and ifosfamide injections
- Enoxaparin (Clexane) injections
- Fludarabine phosphate injection vials
- Gastrografin and Urografin contrast agents (amidotrizoate meglumine and sodium amidotrizoate)
- Gemeprost
- Hydralazine 20 mg injection
- Imipramine tablets
- Intralipid (soya oil) 20% 500 mL infusion bottle
- Isoniazid 100 mg tablets
- Methotrexate (Methoblastin) tablets
- Midodrine tablets
- Phenobarbital sodium (phenobarbitone) 219 mg/1 mL injection ampoule
- Propofol 500 mg/50 mL vials
- Salbutamol solution for inhalation
- Semaglutide, dulaglutide, liraglutide, and tirzepatide
- Silver sulfadiazine 1% w/w cream
- Sodium valproate (Epilim) 100 mg crushable tablets
- Tenofovir disoproxil maleate, emtricitabine and efavirenz tablets 300 mg/200 mg/600 mg
- Tiger Snake Antivenom (equine) 3000 units injection vial

If you need support or assistance with medication safety matters in your facility, please email us:  
[CEC-MedicationSafety@health.nsw.gov.au](mailto:CEC-MedicationSafety@health.nsw.gov.au)